Cargando…
A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats
Aim: Nuclear factor kappa B (NF-κB) is known to play an important role in the inflammatory process which takes place after ischemic stroke. The major objective of the present study was to examine the effects of MEDS-23, a potent inhibitor of NF-κB, on clinical outcomes and brain inflammatory markers...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773493/ https://www.ncbi.nlm.nih.gov/pubmed/35053779 http://dx.doi.org/10.3390/brainsci12010035 |
_version_ | 1784636104441331712 |
---|---|
author | Rubin, Elina Pippione, Agnese C. Boyko, Matthew Einaudi, Giacomo Sainas, Stefano Collino, Massimo Cifani, Carlo Lolli, Marco L. Abu-Freha, Naim Kaplanski, Jacob Boschi, Donatella Azab, Abed N. |
author_facet | Rubin, Elina Pippione, Agnese C. Boyko, Matthew Einaudi, Giacomo Sainas, Stefano Collino, Massimo Cifani, Carlo Lolli, Marco L. Abu-Freha, Naim Kaplanski, Jacob Boschi, Donatella Azab, Abed N. |
author_sort | Rubin, Elina |
collection | PubMed |
description | Aim: Nuclear factor kappa B (NF-κB) is known to play an important role in the inflammatory process which takes place after ischemic stroke. The major objective of the present study was to examine the effects of MEDS-23, a potent inhibitor of NF-κB, on clinical outcomes and brain inflammatory markers in post-ischemic stroke rats. Main methods: Initially, a Toxicity Experiment was performed to determine the appropriate dose of MEDS-23 for use in animals, as MEDS-23 was analyzed in vivo for the first time. We used the middle cerebral artery occlusion (MCAO) model for inducing ischemic stroke in rats. The effects of MEDS-23 (at 10 mg/kg, ip) on post-stroke outcomes (brain inflammation, fever, neurological deficits, mortality, and depression- and anxiety-like behaviours) was tested in several efficacy experiments. Key findings: MEDS-23 was found to be safe and significantly reduced the severity of some adverse post-stroke outcomes such as fever and neurological deficits. Moreover, MEDS-23 significantly decreased prostaglandin E2 levels in the hypothalamus and hippocampus of post-stroke rats, but did not prominently alter the levels of interleukin-6 and tumor necrosis factor-α. Significance: These results suggest that NF-κB inhibition is a potential therapeutic strategy for the treatment of ischemic stroke. |
format | Online Article Text |
id | pubmed-8773493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87734932022-01-21 A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats Rubin, Elina Pippione, Agnese C. Boyko, Matthew Einaudi, Giacomo Sainas, Stefano Collino, Massimo Cifani, Carlo Lolli, Marco L. Abu-Freha, Naim Kaplanski, Jacob Boschi, Donatella Azab, Abed N. Brain Sci Article Aim: Nuclear factor kappa B (NF-κB) is known to play an important role in the inflammatory process which takes place after ischemic stroke. The major objective of the present study was to examine the effects of MEDS-23, a potent inhibitor of NF-κB, on clinical outcomes and brain inflammatory markers in post-ischemic stroke rats. Main methods: Initially, a Toxicity Experiment was performed to determine the appropriate dose of MEDS-23 for use in animals, as MEDS-23 was analyzed in vivo for the first time. We used the middle cerebral artery occlusion (MCAO) model for inducing ischemic stroke in rats. The effects of MEDS-23 (at 10 mg/kg, ip) on post-stroke outcomes (brain inflammation, fever, neurological deficits, mortality, and depression- and anxiety-like behaviours) was tested in several efficacy experiments. Key findings: MEDS-23 was found to be safe and significantly reduced the severity of some adverse post-stroke outcomes such as fever and neurological deficits. Moreover, MEDS-23 significantly decreased prostaglandin E2 levels in the hypothalamus and hippocampus of post-stroke rats, but did not prominently alter the levels of interleukin-6 and tumor necrosis factor-α. Significance: These results suggest that NF-κB inhibition is a potential therapeutic strategy for the treatment of ischemic stroke. MDPI 2021-12-28 /pmc/articles/PMC8773493/ /pubmed/35053779 http://dx.doi.org/10.3390/brainsci12010035 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rubin, Elina Pippione, Agnese C. Boyko, Matthew Einaudi, Giacomo Sainas, Stefano Collino, Massimo Cifani, Carlo Lolli, Marco L. Abu-Freha, Naim Kaplanski, Jacob Boschi, Donatella Azab, Abed N. A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats |
title | A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats |
title_full | A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats |
title_fullStr | A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats |
title_full_unstemmed | A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats |
title_short | A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats |
title_sort | new nf-κb inhibitor, meds-23, reduces the severity of adverse post-ischemic stroke outcomes in rats |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773493/ https://www.ncbi.nlm.nih.gov/pubmed/35053779 http://dx.doi.org/10.3390/brainsci12010035 |
work_keys_str_mv | AT rubinelina anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT pippioneagnesec anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT boykomatthew anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT einaudigiacomo anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT sainasstefano anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT collinomassimo anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT cifanicarlo anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT lollimarcol anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT abufrehanaim anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT kaplanskijacob anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT boschidonatella anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT azababedn anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT rubinelina newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT pippioneagnesec newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT boykomatthew newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT einaudigiacomo newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT sainasstefano newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT collinomassimo newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT cifanicarlo newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT lollimarcol newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT abufrehanaim newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT kaplanskijacob newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT boschidonatella newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats AT azababedn newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats |